Today Novartis announced its Q1 2026 results. While the company noted strong growth in priority brands including Kisqali, Pluvicto, Leqvio, Scemblix, and Kesimpta, sales declined as a result of U.S. generic erosion. Net sales were $13.1 billion for the first quarter.
“Novartis delivered a strong start to 2026 across our priority brands and launches, while US generic erosion weighed on results in Q1 as expected,” Novartis CEO Vas Narasimhan stated in a company announcement. “We continued to advance our pipeline, with compelling Phase III results for remibrutinib in chronic inducible urticaria and Phase II data in food allergy, reinforcing the medicine’s pipeline-in-a-pill potential. We also completed the acquisition of Avidity and announced early-stage deals to support our breast cancer and allergic disease franchises. With the momentum we are seeing across the business, we remain on track to deliver our full year guidance and look forward to multiple readouts in the second half that could raise our mid- to long-term growth outlook.”
The company noted the following innovation milestones for the first quarter:
Remibrutinib positive CHMP opinion for CSU, positive Phase III readout in CIndU and Phase II data in food allergy
Ianalumab FDA Breakthrough Therapy designation and priority review in SjD
Cosentyx FDA approval for pediatric HS patients, regulatory submissions for PMR
Fabhalta positive Phase III eGFR results in IgAN, FDA priority review for traditional approval
Completed acquisition of Avidity, adding three late-stage medicines addressing neuromuscular disease
Read the full details of the Novartis announcement.